Siemens PETNET Solutions Expands Imaging Biomarker Production Capabilities in the UK

Siemens PETNET Solutions Expands Imaging Biomarker Production Capabilities in the UK
Knoxville, Tenn., October 8, 2010 - Siemens PETNET Solutions; A Division of Siemens PLC, announced today the expansion of its imaging biomarker production capabilities in Nottingham, England to include the ability to produce new biomarkers as investigational medicine products (IMP) in the United Kingdom. These IMPs include a proprietary hypoxic agent developed by Siemens for identification of tumor tissues with low oxygen supply, and a leading investigational amyloid agent, for PET imaging of β-amyloid deposits in the brain.

PETNET Solutions' recent and significant investments to build radiopharmaceutical manufacturing and distribution capabilities in areas, such as the UK, support its own global growth strategy, as well as the commercialization of new imaging agents. Siemens and third-party evaluations for new drugs or treatments can be facilitated by the worldwide manufacturing and distribution of radiopharmaceuticals from PETNET solutions.

PETNET Solutions operates the largest network of PET radiopharmaceutical production facilities with 54 production and distribution centers worldwide.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source - from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2009 (to September 30), the Sector posted revenue of 11.9 billion euros and profit of around 1.5 billion euros. For further information please visit:

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.